Sebastià Rubí , Pedro Bibilioni , Marina Villar , Marta Brell , Manuel Valiente , Margalida Galmés , María Toscano , Gabriel Matheu , José Luis Chinchilla , Jesús Molina , José Luis Valera , Ángel Ríos , Meritxell López , Cristina Peña
{"title":"Full kinetic modeling analysis of [18F]fluorocholine Positron Emission Tomography (PET) at initial diagnosis of high-grade glioma","authors":"Sebastià Rubí , Pedro Bibilioni , Marina Villar , Marta Brell , Manuel Valiente , Margalida Galmés , María Toscano , Gabriel Matheu , José Luis Chinchilla , Jesús Molina , José Luis Valera , Ángel Ríos , Meritxell López , Cristina Peña","doi":"10.1016/j.nicl.2024.103616","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><p>The main objective was to characterize the tracer uptake kinetics of [<sup>18</sup>F]fluoromethylcholine ([<sup>18</sup>F]F-CHO) in high-grade gliomas (HGG) through a full PET kinetic modeling approach. Secondarily, we aimed to explore the relationship between the PET uptake measures and the HGG molecular features.</p></div><div><h3>Materials and methods</h3><p>Twenty-four patients with a suspected diagnosis of HGG were prospectively included. They underwent a dynamic brain [<sup>18</sup>F]F-CHO-PET/CT, from which a tumoral time-activity curve was extracted. The plasma input function was obtained through arterial blood sampling with metabolite correction. These data were fitted to 1- and 2-tissue-compartment models, the best of which was selected through the Akaike information criterion. We assessed the correlation between the kinetic parameters and the conventional static PET metrics (SUV<sub>max</sub>, SUV<sub>mean</sub> and tumor-to-background ratio TBR). We explored the association between the [<sup>18</sup>F]F-CHO-PET quantitative parameters and relevant molecular biomarkers in HGG.</p></div><div><h3>Results</h3><p>Tumoral time-activity curves in all patients showed a rapid rise of [<sup>18</sup>F]F-CHO uptake followed by a plateau-like shape. Best fits were obtained with near-irreversible 2-tissue-compartment models. The perfusion-transport constant K<sub>1</sub> and the net influx rate K<sub>i</sub> showed strong correlation with SUV<sub>max</sub> (r = 0.808–0.861), SUV<sub>mean</sub> (r = 0.794–0.851) and TBR (r = 0.643–0.784), p < 0.002. HGG was confirmed in 21 patients, of which those with methylation of the O-6-methylguanine-DNA methyltransferase (MGMT) gene promoter showed higher mean K<sub>i</sub> (p = 0.020), K<sub>1</sub> (p = 0.025) and TBR (p = 0.001) than the unmethylated ones.</p></div><div><h3>Conclusion</h3><p>[<sup>18</sup>F]F-CHO uptake kinetics in HGG is best explained by a 2-tissue-compartment model. The conventional static [<sup>18</sup>F]F-CHO-PET measures have been validated against the perfusion-transport constant (K<sub>1</sub>) and the net influx rate (K<sub>i</sub>) derived from kinetic modeling. A relationship between [<sup>18</sup>F]F-CHO uptake rate and MGMT methylation is suggested but needs further confirmation.</p></div>","PeriodicalId":54359,"journal":{"name":"Neuroimage-Clinical","volume":null,"pages":null},"PeriodicalIF":3.4000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S221315822400055X/pdfft?md5=978f75cea4039fe6464cc401f408db2d&pid=1-s2.0-S221315822400055X-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuroimage-Clinical","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S221315822400055X","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"NEUROIMAGING","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose
The main objective was to characterize the tracer uptake kinetics of [18F]fluoromethylcholine ([18F]F-CHO) in high-grade gliomas (HGG) through a full PET kinetic modeling approach. Secondarily, we aimed to explore the relationship between the PET uptake measures and the HGG molecular features.
Materials and methods
Twenty-four patients with a suspected diagnosis of HGG were prospectively included. They underwent a dynamic brain [18F]F-CHO-PET/CT, from which a tumoral time-activity curve was extracted. The plasma input function was obtained through arterial blood sampling with metabolite correction. These data were fitted to 1- and 2-tissue-compartment models, the best of which was selected through the Akaike information criterion. We assessed the correlation between the kinetic parameters and the conventional static PET metrics (SUVmax, SUVmean and tumor-to-background ratio TBR). We explored the association between the [18F]F-CHO-PET quantitative parameters and relevant molecular biomarkers in HGG.
Results
Tumoral time-activity curves in all patients showed a rapid rise of [18F]F-CHO uptake followed by a plateau-like shape. Best fits were obtained with near-irreversible 2-tissue-compartment models. The perfusion-transport constant K1 and the net influx rate Ki showed strong correlation with SUVmax (r = 0.808–0.861), SUVmean (r = 0.794–0.851) and TBR (r = 0.643–0.784), p < 0.002. HGG was confirmed in 21 patients, of which those with methylation of the O-6-methylguanine-DNA methyltransferase (MGMT) gene promoter showed higher mean Ki (p = 0.020), K1 (p = 0.025) and TBR (p = 0.001) than the unmethylated ones.
Conclusion
[18F]F-CHO uptake kinetics in HGG is best explained by a 2-tissue-compartment model. The conventional static [18F]F-CHO-PET measures have been validated against the perfusion-transport constant (K1) and the net influx rate (Ki) derived from kinetic modeling. A relationship between [18F]F-CHO uptake rate and MGMT methylation is suggested but needs further confirmation.
期刊介绍:
NeuroImage: Clinical, a journal of diseases, disorders and syndromes involving the Nervous System, provides a vehicle for communicating important advances in the study of abnormal structure-function relationships of the human nervous system based on imaging.
The focus of NeuroImage: Clinical is on defining changes to the brain associated with primary neurologic and psychiatric diseases and disorders of the nervous system as well as behavioral syndromes and developmental conditions. The main criterion for judging papers is the extent of scientific advancement in the understanding of the pathophysiologic mechanisms of diseases and disorders, in identification of functional models that link clinical signs and symptoms with brain function and in the creation of image based tools applicable to a broad range of clinical needs including diagnosis, monitoring and tracking of illness, predicting therapeutic response and development of new treatments. Papers dealing with structure and function in animal models will also be considered if they reveal mechanisms that can be readily translated to human conditions.